| 摘要 |
<p>The present invention provides a method of preventing or treating retinal degeneration arising from pathophysiological or physical conditions. The method comprises administering to a patient a pharmaceutical composition comprising a purinergic P2Y receptor ligand, in an amount effective to elevate its extracellular concentration to activate retinal glial and neuronal cell surface P2Y receptors and mount a neuroprotective response. Methods of administering including intravitreal bolus and sustained administrations, transscleral delivery, topical, and systemic administrations. The pharmaceutical composition useful in this invention comprises a P2Y purinergic receptor agonist, which include uridine 5'-di -and triphosphate (UDP, UTP) and their analogs, adenosine 5'-diphosphate (ADP) and its analogs, cytidine 5'-di- and triphosphate (CDP, CTP) and their analogs, and dinucleoside polyphosphate compounds.</p> |
